Therma Bright’s International Patent Application for TherOZap(TM) Enters National Phases in the US, Europe & Canada


Toronto, Ontario–(Newsfile Corp. – September 5, 2019) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, today announces that the TherOZap™ technology under the Company’s former name, The Jenex Corporation, has filed an international patent application under the PCT convention for its thermal therapy TherOZap™ and has recently entered the national phases in the US, Europe and Canada. In the international phase, the international search report found all searched claims to be novel. In the national phases, the claims will be further examined for patentability and allowance is expected. Therma is in the process of changing the international patent application name to: Therma Bright Inc. from the former name, The Jenex Corporation. 

Rob Fia, CEO, commented:

“Further to our press release on September 4rd, 2019 highlighting that our TherOZap™ technology proves successful at inhibiting the Zika virus during in-vitro tests, we are pleased to announce that Therma is strengthening its intellectual property portfolio. 

Our Company has come up with novel ideas on how to potentially combat mosquito borne diseases using advanced technology. The fact that the international search report found all searched claims to be novel, confirms that Therma is on the right track and we intend to protect our TherOZap™ intellectual property and other ideas for the benefit of Therma shareholders.”